Published in Oncogene on September 18, 2008
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell (2010) 5.67
Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell (2010) 5.47
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2009) 3.35
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A (2009) 3.26
Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev (2013) 3.21
Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 3.03
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal (2010) 2.64
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 2.45
Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther (2009) 2.43
Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol (2014) 2.36
Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer (2010) 2.35
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34
PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res (2009) 2.32
Colorectal cancer molecular biology moves into clinical practice. Gut (2010) 2.32
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res (2010) 2.30
PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov (2011) 2.14
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A (2011) 2.14
RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer (2011) 2.12
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell (2014) 2.09
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
Energy balance, host-related factors, and cancer progression. J Clin Oncol (2010) 1.85
Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A (2010) 1.83
mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell (2010) 1.82
Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Mol Cancer (2014) 1.81
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest (2012) 1.79
IQGAP1 and its binding proteins control diverse biological functions. Cell Signal (2011) 1.77
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov (2011) 1.77
Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res (2010) 1.76
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet (2012) 1.74
LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol (2013) 1.73
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer (2009) 1.70
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res (2012) 1.70
Lipid activation of protein kinases. J Lipid Res (2008) 1.68
Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol (2012) 1.67
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci U S A (2010) 1.61
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev (2012) 1.60
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene (2010) 1.56
Mutations in phosphoinositide metabolizing enzymes and human disease. Physiology (Bethesda) (2009) 1.56
Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation. J Cell Biol (2011) 1.56
Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2. Cell Metab (2013) 1.54
Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s). Genes Cancer (2010) 1.53
Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res (2013) 1.46
The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med (2009) 1.43
Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J Biol Chem (2010) 1.42
Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One (2010) 1.41
Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A (2010) 1.40
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle (2008) 1.40
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov (2013) 1.38
CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med (2009) 1.38
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst (2013) 1.38
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer (2010) 1.38
Proton-assisted amino-acid transporters are conserved regulators of proliferation and amino-acid-dependent mTORC1 activation. Oncogene (2010) 1.37
Differential 14-3-3 affinity capture reveals new downstream targets of phosphatidylinositol 3-kinase signaling. Mol Cell Proteomics (2009) 1.35
PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev (2009) 1.32
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res (2011) 1.32
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res (2009) 1.31
Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem (2010) 1.27
Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death. Cell Death Differ (2012) 1.27
Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul (2014) 1.27
Inositol polyphosphate multikinase is a physiologic PI3-kinase that activates Akt/PKB. Proc Natl Acad Sci U S A (2011) 1.27
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev (2009) 1.26
mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle (2012) 1.25
SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells. J Immunol (2010) 1.25
Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. Nat Med (2012) 1.23
A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2010) 1.23
Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int (2012) 1.23
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood (2009) 1.23
Protein kinases and phosphatases in the control of cell fate. Enzyme Res (2011) 1.23
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl (2014) 1.23
Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer (2010) 1.22
An evolutionarily conserved Rit GTPase-p38 MAPK signaling pathway mediates oxidative stress resistance. Mol Biol Cell (2011) 1.22
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A (2011) 1.21
Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis. Retrovirology (2009) 1.21
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A (2014) 1.20
CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat Commun (2012) 1.18
Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer (2011) 1.18
Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations. Curr Biol (2011) 1.18
Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther (2009) 1.18
Selection in spatial stochastic models of cancer: migration as a key modulator of fitness. Biol Direct (2010) 1.17
EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J (2011) 1.17
Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes. J Exp Med (2009) 1.16
Dysregulation of RNA polymerase I transcription during disease. Biochim Biophys Acta (2012) 1.16
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med (2010) 1.15
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Cancer metastasis: building a framework. Cell (2006) 19.67
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Putting tumours in context. Nat Rev Cancer (2001) 12.37
Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
Tenets of PTEN tumor suppression. Cell (2008) 8.61
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science (2000) 6.26
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell (2000) 5.23
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science (2007) 5.19
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol (2007) 4.67
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol (1994) 4.49
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 3.98
Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature (1999) 3.81
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res (2007) 3.51
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res (2006) 3.31
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res (2007) 3.21
Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature (2008) 3.19
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007) 3.17
Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol (1996) 3.08
The regulation of cell motility and chemotaxis by phospholipid signaling. J Cell Sci (2008) 3.04
The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer (2005) 2.83
Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem (2004) 2.73
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer (2008) 2.68
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 2.62
The role of PI3K in immune cells. Nat Immunol (2003) 2.41
PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol (2007) 2.40
Regulation of cell polarity during epithelial morphogenesis. Curr Opin Cell Biol (2008) 2.40
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell (2005) 2.39
Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci U S A (2004) 2.39
Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol (2006) 2.34
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res (2008) 2.30
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther (2006) 2.25
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev (2005) 2.18
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst (2006) 2.00
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. Clin Cancer Res (2007) 1.98
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene (2007) 1.84
Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res (2003) 1.80
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer (2007) 1.79
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther (2007) 1.62
Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res (2002) 1.61
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer (2006) 1.61
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene (2008) 1.46
Activation of phosphoinositide 3-kinase gamma by Ras. Curr Biol (2002) 1.39
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer (2007) 1.31
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci (2007) 1.30
The PI3K inhibitor arsenal: choose your weapon! Trends Biochem Sci (2007) 1.26
Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol (1996) 1.25
Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. Int J Gynecol Cancer (2008) 1.18
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther (2008) 1.16
Covalent reactions of wortmannin under physiological conditions. Chem Biol (2007) 1.15
Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle (2007) 1.15
Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol Ther (2008) 1.13
Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost (2007) 1.10
Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat (2006) 1.08
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell (2006) 1.05
Fate of a bioactive fluorescent wortmannin derivative in cells. Bioconjug Chem (2007) 1.05
Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer. Oncol Rep (2000) 1.05
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res (2005) 1.03
An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol (2006) 1.00
The structural basis for 14-3-3:phosphopeptide binding specificity. Cell (1997) 10.87
Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science (1997) 8.81
Phosphoinositide kinases. Annu Rev Biochem (1998) 8.51
Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science (1997) 8.16
PI3K: downstream AKTion blocks apoptosis. Cell (1997) 7.73
Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature (1997) 7.20
A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nat Biotechnol (2001) 6.50
PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell (1989) 6.26
Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr Biol (1994) 6.04
Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science (1997) 5.40
Vanadate is a potent (Na,K)-ATPase inhibitor found in ATP derived from muscle. J Biol Chem (1977) 5.16
Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell (1996) 5.10
Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science (1999) 4.77
Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem (1990) 4.75
The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. Nat Cell Biol (2001) 4.64
The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem (1999) 4.62
A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol (1996) 4.61
TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J (2000) 4.55
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A (1994) 4.51
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol (1994) 4.49
Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell (1995) 4.32
Activation of phosphatidylinositol 3-kinase by insulin. Proc Natl Acad Sci U S A (1990) 4.32
Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science (1999) 4.20
Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding. Mol Cell (1999) 4.02
Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem (1997) 3.86
Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci U S A (1984) 3.84
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science (1997) 3.73
A characterization of vanadate interactions with the (Na,K)-ATPase. Mechanistic and regulatory implications. J Biol Chem (1978) 3.67
Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J Biol Chem (2000) 3.66
The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J (2000) 3.64
Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation. J Cell Biol (2001) 3.63
Rho family GTPases bind to phosphoinositide kinases. J Biol Chem (1995) 3.49
A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate. Nature (1997) 3.29
Phosphatidylinositol 3-kinase. Bioessays (1994) 3.27
A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains. J Biol Chem (1997) 3.19
Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem (1993) 3.14
Activation of protein kinase C family members by the novel polyphosphoinositides PtdIns-3,4-P2 and PtdIns-3,4,5-P3. J Biol Chem (1994) 3.08
Phosphoinositide kinases. Curr Opin Cell Biol (1996) 3.01
Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol (2001) 2.93
Corequirement of specific phosphoinositides and small GTP-binding protein Cdc42 in inducing actin assembly in Xenopus egg extracts. J Cell Biol (1998) 2.90
In vivo near-infrared fluorescence imaging of osteoblastic activity. Nat Biotechnol (2001) 2.89
Stimulation of the T3-T cell receptor complex induces a membrane-potential-sensitive calcium influx. Cell (1985) 2.69
Identification and quantification of polyphosphoinositides produced in response to platelet-derived growth factor stimulation. Methods Enzymol (1991) 2.69
SRPK2: a differentially expressed SR protein-specific kinase involved in mediating the interaction and localization of pre-mRNA splicing factors in mammalian cells. J Cell Biol (1998) 2.69
Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci U S A (1997) 2.64
A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell (1994) 2.64
The erbB3 gene product is a receptor for heregulin. J Biol Chem (1994) 2.63
Phosphoinositide kinases. Biochemistry (1990) 2.56
The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell (2001) 2.53
Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts. Mol Cell Biol (1993) 2.47
Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J Biol Chem (2000) 2.42
Sequence requirements for the recognition of tyrosine-based endocytic signals by clathrin AP-2 complexes. EMBO J (1996) 2.42
Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet (2000) 2.39
Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Cell (1995) 2.34
United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans (2003) 2.34
Recognition and specificity in protein tyrosine kinase-mediated signalling. Trends Biochem Sci (1995) 2.31
Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J (1998) 2.29
Vanadate inhibits the red cell (Na+, K+) ATPase from the cytoplasmic side. Nature (1978) 2.27
Interaction of Shc with the zeta chain of the T cell receptor upon T cell activation. Science (1993) 2.25
Regulatory interactions in the recognition of endocytic sorting signals by AP-2 complexes. EMBO J (1997) 2.19
The SH3 domain of amphiphysin binds the proline-rich domain of dynamin at a single site that defines a new SH3 binding consensus sequence. J Biol Chem (1997) 2.16
Polyphosphoinositides produced by phosphatidylinositol 3-kinase are poor substrates for phospholipases C from rat liver and bovine brain. J Biol Chem (1989) 2.15
The use of peptide library for the determination of kinase peptide substrates. Methods Mol Biol (1998) 2.12
Signal transduction and membrane traffic: the PITP/phosphoinositide connection. Cell (1995) 2.11
Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J (1997) 2.09
Biochemical interactions integrating Itk with the T cell receptor-initiated signaling cascade. J Biol Chem (2000) 2.08
Lipid second messengers. Cell (1994) 2.07
Isolation of a potent (Na-K)ATPase inhibitor from striated muscle. Biochemistry (1977) 2.07
Type Ialpha phosphatidylinositol-4-phosphate 5-kinase mediates Rac-dependent actin assembly. Curr Biol (2000) 2.00
A tightly associated serine/threonine protein kinase regulates phosphoinositide 3-kinase activity. Mol Cell Biol (1993) 1.95
The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70. J Biol Chem (1997) 1.87
Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol (2012) 1.83
Regulation of GRP1-catalyzed ADP ribosylation factor guanine nucleotide exchange by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 1.83
Novel function of phosphatidylinositol 4,5-bisphosphate as a cofactor for brain membrane phospholipase D. J Biol Chem (1994) 1.82
Subcellular locations of phosphatidylinositol 4-kinase isoforms. J Biol Chem (1997) 1.81
Regulation of c-Src tyrosine kinase activity by the Src SH2 domain. Oncogene (1993) 1.79
The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem (1991) 1.71
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol (1991) 1.68
Mapping specificity determinants for protein-protein association using protein fusions and random peptide libraries. Methods Enzymol (2000) 1.66
Src-homology 3 domain of protein kinase p59fyn mediates binding to phosphatidylinositol 3-kinase in T cells. Proc Natl Acad Sci U S A (1993) 1.62
Characterization of a Rac1- and RhoGDI-associated lipid kinase signaling complex. Mol Cell Biol (1998) 1.60
Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci U S A (1997) 1.57
Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. J Biol Chem (1995) 1.57
Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J Biol Chem (1995) 1.57
Analysis of an activator:coactivator complex reveals an essential role for secondary structure in transcriptional activation. Mol Cell (1998) 1.56
Conditional inhibition of the mitogen-activated protein kinase cascade by wortmannin. Dependence on signal strength. J Biol Chem (1997) 1.54
Phosphatidylinositol 3-kinase and its novel product, phosphatidylinositol 3-phosphate, are present in Saccharomyces cerevisiae. J Biol Chem (1989) 1.53
Polyoma virus middle T antigen-pp60c-src complex associates with purified phosphatidylinositol 3-kinase in vitro. J Biol Chem (1992) 1.52
Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis. J Clin Invest (2001) 1.51
The lipid products of phosphoinositide 3-kinase increase cell motility through protein kinase C. J Biol Chem (1997) 1.47
Identification of two SH3-binding motifs in the regulatory subunit of phosphatidylinositol 3-kinase. J Biol Chem (1994) 1.47
Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol Cell (1999) 1.47
Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene. Genomics (1996) 1.47
Signal transduction. Grabbing phosphoproteins. Nature (1999) 1.46
Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase. J Biol Chem (1992) 1.44
SH2 domain specificity and activity modified by a single residue. Nature (1994) 1.44
Phosphoinositide 3-kinase regulates phospholipase Cgamma-mediated calcium signaling. J Biol Chem (1998) 1.40
Cloning and characterization of a wortmannin-sensitive human phosphatidylinositol 4-kinase. J Biol Chem (1997) 1.40
Marked differences between metalloproteases meprin A and B in substrate and peptide bond specificity. J Biol Chem (2001) 1.38